This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Psoriasis: regaining efficacy with secukinumab following loss of response

Takeaway

  • Secukinumab (Cosentyx) is associated with stable efficacy at 52 weeks in a majority of patients with moderate-to-severe psoriasis in post hoc analyses of the FIXTURE and CLEAR trials.

Why this matters

  • This analysis adds further support for sustained efficacy of secukinumab.

Key results

  • In the CLEAR trial at 52 weeks, 90.2% of patients showed stable efficacy without loss of response and 77.7% showed stable efficacy without reduction of response (compared with 74.2% and 59.9%, respectively, of patients who received ustekinumab (Stelara).
  • In the FIXTURE trial at 52 weeks, 83.5% of patients showed stable efficacy without loss of response and 66.4% of patients showed stable efficacy without reduction of response (compared with 58.3% and 42.6%, respectively, of patients who received etanercept (Enbrel).
  • Of patients who experienced loss of response, 50.0% (CLEAR trial) and 26.5% (FIXTURE trial) regained response by continuing secukinumab.

Study design

  • CLEAR included 336 patients who received secukinumab and 339 who received ustekinumab.
  • FIXTURE included 327 patients who received secukinumab and 326 patients who received etanercept.
  • Response categories were defined based on Psoriasis Area and Severity Index reduction from baseline.
  • Funding: Novartis Pharma GmbH

Limitations

  • Post hoc analysis limits statistical analysis and comparisons between trials.

References


YOU MAY ALSO LIKE